mafenide (Sulfamylon)
Jump to navigation
Jump to search
Introduction
Withdrawn from U.S. market by maker Viatris[2]
Indications
- antibacterial burn cream containing mafenid with good penetration for deep injury
- sunburn
Adverse effects
- bicarbonate-diuresis resulting in metabolic acidosis
Mechanism of action
More general terms
References
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 2558
- ↑ 2.0 2.1 Brennan Z Viatris withdraws accelerated approval for topical antimicrobial 24 years later. EndpointsNews. Nov 29, 2022 https://endpts.com/viatris-withdraws-accelerated-approval-for-topical-antimicrobial-24-years-later/